Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 27 Apr 2017
Price : $35 *
At a glance
- Drugs Rifaximin (Primary) ; Ciprofloxacin
- Indications Bacterial peritonitis
- Focus Registrational; Therapeutic Use
- 24 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 01 Dec 2014 Status changed from not yet recruiting to recruiting as per ClinicalTrial.gov record.
- 22 Dec 2013 New trial record